Renal cell carcinoma and urothelial malignancies
Research activity centers on advanced clear cell renal cell carcinoma, non-clear cell renal cell carcinoma, and broader metastatic renal cell carcinoma, with attention to treatment settings spanning first-line through later-line care. The portfolio also includes bladder cancer and urothelial carcinoma, including both ICI-naïve and ICI-experienced disease.
- Advanced clear cell renal cell carcinoma
- Non-clear cell renal cell carcinoma
- Urothelial carcinoma
- Bladder cancer
These studies reflect sustained interest in kidney and urinary tract cancers, with emphasis on difficult-to-treat metastatic disease.
Prostate cancer and genitourinary oncology
The sponsor funds research in metastatic castration-resistant prostate cancer, including patients previously treated with novel hormonal therapy. This area sits alongside its broader focus on advanced genitourinary cancers.
- Metastatic castration-resistant prostate cancer
- Second-line post-NHT disease
- Advanced genitourinary cancer
Clinical interest is directed toward resistant disease states where standard hormonal approaches are no longer sufficient.
Liver, thyroid, and gastrointestinal cancers
Trials also address hepatocellular carcinoma, radioiodine-refractory differentiated thyroid cancer, progressed thyroid cancer, and colorectal cancer, including metastatic colorectal cancer and MSS/MSI-low disease. The program extends to metastatic medullary thyroid cancer and other advanced solid tumors in these domains.
- Hepatocellular carcinoma
- Radioiodine-refractory differentiated thyroid cancer
- Metastatic colorectal cancer
- Metastatic medullary thyroid cancer
These studies focus on tumor types with limited treatment options after disease progression.
Head and neck and thoracic oncology
Exelixis also supports research in recurrent or metastatic head and neck squamous cell carcinoma, head and neck squamous cell carcinoma, and non-small cell lung cancer. The portfolio includes combinations studied in solid tumors with relevance to these disease areas.
- Head and neck squamous cell carcinoma
- Recurrent or metastatic HNSCC
- Non-small cell lung cancer
- Advanced solid tumors
These programs address aggressive cancers with substantial unmet need in advanced and metastatic settings.
Neuroendocrine and other advanced solid tumors
The sponsor’s research landscape includes neuroendocrine tumors and advanced solid tumors across multiple histologies, including disease settings where life-prolonging therapies are unavailable, intolerable, or no longer effective. This encompasses studies spanning a wide range of refractory tumor types.
- Neuroendocrine tumors
- Advanced solid tumors
- Refractory metastatic cancers
Interest in these indications reflects a broad therapeutic reach across late-stage oncology.
